Genmab Net Income 2019-2022 | GMAB

Genmab annual/quarterly net income history and growth rate from 2019 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Genmab net income for the quarter ending March 31, 2022 was $0.070B, a 60.53% decline year-over-year.
  • Genmab net income for the twelve months ending March 31, 2022 was $0.371B, a 57.2% decline year-over-year.
  • Genmab annual net income for 2021 was $0.479B, a 34.35% decline from 2020.
  • Genmab annual net income for 2020 was $0.729B, a 124.5% increase from 2019.
  • Genmab annual net income for 2019 was $0.325B, a 39.24% increase from 2018.
Genmab Annual Net Income
(Millions of US $)
2021 $479
2020 $729
2019 $325
2018 $233
Genmab Quarterly Net Income
(Millions of US $)
2022-03-31 $70
2021-12-31 $110
2021-09-30 $141
2021-06-30 $50
2021-03-31 $178
2020-12-31 $107
2020-09-30 $83
2020-06-30 $499
2020-03-31 $40
2019-12-31 $221
2019-09-30 $80
2019-06-30 $13
2019-03-31 $11
2018-12-31 $132
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $19.595B $1.349B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00